Abstract
We studied the usefulness of cefodizime (THR-221) in urinary tract infection (UTI) in bacteriological and clinical studies. The antimicrobial activity of THR-221 against S. epidennidis, E. faecalis, E. coli, K. pneumoniae, S. marcescens and P. aeruginosa, all of which were isolated from the urinary tract, was compared with that of cefotaxime (CTX) and cefoperazone (CPZ). Although the antimicrobial activity of THR-221 against E. coli, K. pneumoniae and S. marcescens was equal to that of CTX and CPZ, against P. aeruginosa it was inferior to CPZ.
THR-221, 2 g b.i.d. was given to 10 patients with complicated UTI for 5 days. The overall efficacy rate was 55.6% for 9 cases, fulfilling the criteria of the UTI Committee for evaluation of clinical efficacy of antimicrobial agents on UTI. Fourteen strains (except 1 each of E. faecium, P. aeruginosa and P. cepacia) of bacteria isolated before treatment were eradicated, the eradication rate being 82.4%. Although aggravations in laboratory tests were observed in two cases, these episodes were mild and THR-221 therapy was not stopped, No subjective or objective side-effects were observed. Our results suggest that THR-221 is effective and safe in the treatment of UTI.
